Overview

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Status:
Unknown status

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

This prospective study was conducted to evaluate the efficacy and safety profiles of Modified MRCUKALLⅫ/ECOGE2993 Regimen in young adults with newly diagnosed, low-risk, Philadelphia chromosome negative acute lymphoblastic leukaemia.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

6-Mercaptopurine
BB 1101
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Etoposide phosphate
Mercaptopurine
Methotrexate
Pegaspargase
Prednisone
Thioguanine
Vincristine